A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients With the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome.
Latest Information Update: 07 May 2024
At a glance
- Drugs Fasudil (Primary)
- Indications Corticobasal degeneration
- Focus Adverse reactions; Biomarker
- Acronyms ROCKIT-1
- Sponsors Woolsey Pharmaceuticals
- 31 May 2022 Planned End Date changed from 30 Jul 2022 to 30 Nov 2023.
- 31 May 2022 Planned primary completion date changed from 30 Jul 2022 to 30 Nov 2022.
- 05 Jan 2022 Status changed from recruiting to active, no longer recruiting.